Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39554 | 0.82 | HSPA5 (0.66) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL29500375 | 0.82 | HSPA5 (0.66) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL30903568 | 0.82 | HSPA5 (0.66) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL30578552 | 0.81 | HSPA5 (0.53) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL12324715 | 0.80 | HSPA5 (0.49) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL3685892 | 0.80 | HSPA5 (0.63) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL2786708 | 0.80 | CYP2C19 (0.67) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL7110304 | 0.78 | CYP2C9 (0.52) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL16320620 | 0.77 | HSPA5 (0.45) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL4457370 | 0.74 | HSPA5 (0.62) | HSPA5CYP2C19CYP2C9HIF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1170296-B1 | Process for the preparation of 3-aryl-benzofuran-2-ones | CIBA SC HOLDING AG (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-6586606-B2 | By hydrolyzing the corresponding 2-aminobenzofuran; use as stabilizer against oxidative, thermal, or light-induced degradation in lubricants, fuels, polymers, and hydraulic or metal working fluids | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-20020115855-A1 | Process for the preparation of 3-aryl-benzofuran-2-ones | CIBA SPECIALTY CHEMICALS CORP. | 2002-08-22 | — | — | US | disclosed |
| EP-1170296-A2 | Process for the preparation of 3-aryl-benzofuran-2-ones | Ciba SC Holding AG (CH) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115855-A1 | Process for the preparation of 3-aryl-benzofuran-2-ones | CYP1B1, CYP1A1, SULT1A1 | HSPA5 369/4885CYP2C19 34/4885CYP2C9 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.